EVT.DE - Evotec SE

XETRA - XETRA Delayed Price. Currency in EUR
20.89
+0.36 (+1.75%)
At close: 5:35PM CEST
Stock chart is not supported by your current browser
Previous Close20.53
Open20.77
Bid0.00 x 105300
Ask0.00 x 169300
Day's Range20.38 - 20.97
52 Week Range14.99 - 27.29
Volume1,367,971
Avg. Volume1,175,076
Market Cap3.126B
Beta (3Y Monthly)1.20
PE Ratio (TTM)41.12
EPS (TTM)0.51
Earnings DateNov 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.19
  • Evotec (ETR:EVT) Has A Rock Solid Balance Sheet
    Simply Wall St.

    Evotec (ETR:EVT) Has A Rock Solid Balance Sheet

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • ACCESSWIRE

    Evotec to Attend Upcoming Investor Conferences

    HAMBURG, GERMANY / ACCESSWIRE / September 6, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at and attending the ...

  • I Ran A Stock Scan For Earnings Growth And Evotec (ETR:EVT) Passed With Ease
    Simply Wall St.

    I Ran A Stock Scan For Earnings Growth And Evotec (ETR:EVT) Passed With Ease

    Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...

  • ACCESSWIRE

    Evotec Se Reports First Half-Year 2019 Results And Corporate Updates

    STRONG FIRST HALF YEAR WITH 16% INCREASE IN GROUP REVENUES, 51% EBITDA INCREASE; STRONG OUTLOOK FOR THE YEAR - GUIDANCE INCREASED SIGNIFICANT PROGRESS IN ALL SERVICES, ALLIANCES & CO-OWNED PIPELINE IMPORTANT ...

  • ACCESSWIRE

    EVOTEC SE to Report First Half-Year 2019 Results on 14 August 2019

    HAMBURG, GERMANY / ACCESSWIRE / August 7, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) will report its financial results for the first half of 2019 on Wednesday, 14 ...

  • ACCESSWIRE

    Evotec SE: New IMI project 'GNA Now' kicks off its Battle Against Antimicrobial Resistance

    HAMBURG, GERMANY and UTRECHT, NETHERLANDS / ACCESSWIRE / August 1, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and Lygature announced their cooperation in a new initiative for the development of novel antibacterial agents today: Gram-Negative Antibacterials NOW ("GNA NOW"). The new GNA NOW project, led by Evotec SE, managed by Lygature and funded by the Innovative Medicines Initiative (IMI), will work on the development of novel antibacterial agents to battle antimicrobial resistance in gram-negative bacteria.

  • ACCESSWIRE

    Evotec Se: P2x3 Antagonist Demonstrates Efficacy Against Refractory Chronic Cough In Phase Ii (Poc)

    HAMBURG, GERMANY / ACCESSWIRE / July 25, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the Company has been notified by its partner Bayer about the successful outcome of a combined Phase I/IIa study with the P2X3 antagonist BAY1817080, originating from the Evotec/Bayer multi-target alliance. The objective of the study was to evaluate the safety, efficacy and dose range of BAY1817080 in patients with refractory chronic cough. Under the agreement from 2012, Evotec would be entitled to its next financial milestone payment upon start of a Phase III clinical study, to be decided by Bayer.

  • ACCESSWIRE

    Evotec SE: Positive Phase II data for P2X3 antagonist in patients with refractory chronic cough

    HAMBURG, GERMANY / ACCESSWIRE / July 25, 2019 / Evotec SE (Frankfurt Stock Exchange, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480) announced today that the Company has been informed by Bayer about positive ...

  • Here's What Evotec SE's (ETR:EVT) P/E Is Telling Us
    Simply Wall St.

    Here's What Evotec SE's (ETR:EVT) P/E Is Telling Us

    The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll apply a basic P/E...

  • ACCESSWIRE

    Evotec Expands Its IPSC Discovery Platform

    ACQUIRED ASSETS FROM NCARDIA AG INCLUDE IP PORTFOLIO, IPSC-BASED CELLULAR PRODUCTS AND AN EXPERIENCED STEM CELL BIOLOGY TEAM EXPANSION OF IPSC DISCOVERY PLATFORM STRENGTHENS EVOTEC'S POSITION AS A LEADER ...

  • ACCESSWIRE

    Evotec And Venture Capital Consortium Form 'Breakpoint Therapeutics Gmbh'

    PORTFOLIO OF DRUG DISCOVERY PROJECTS TARGETING DNA DAMAGE RESPONSES ("DDR"), A HIGHLY PROMISING APPROACH TO TREAT CANCER PATIENTS BREAKPOINT THERAPEUTICS WILL ADVANCE MULTIPLE COMPLEMENTARY AND ...

  • ACCESSWIRE

    Evotec Completes Acquisition Of Just Biotherapeutics

    ACQUISITION EXTENDS EVOTEC'S MULTIMODALITY OFFERING, WITH INTEGRATED SOLUTIONS FOR SMALL MOLECULES AND BIOLOGICS EXPANDS EVOTEC'S US FOOTPRINT IN SEATTLE AND MACHINE LEARNING CAPABILITIES DEAL VALUE OF ...

  • Does Evotec SE's (ETR:EVT) CEO Salary Reflect Performance?
    Simply Wall St.

    Does Evotec SE's (ETR:EVT) CEO Salary Reflect Performance?

    Werner Lanthaler became the CEO of Evotec SE (ETR:EVT) in 2013. This analysis aims first to contrast CEO compensation...

  • ACCESSWIRE

    Evotec Se Places First Schuldschein (Promissory Note) Worth Eur 250 M

    PROCEEDS TO BE USED FOR GENERAL CORPORATE FINANCING INCLUDING FINANCING OF JUST.BIO ACQUISITION, EXPANSION, AND REFINANCING STRONG PERFORMANCE AND OUTLOOK OF THE COMPANY APPEALS TO DEBT INVESTORS AND RESULTS ...

  • ACCESSWIRE

    Evotec, Sensyne Health, The University Of Oxford, OSI, and OUI Create New Bridge Partnership 'LAB10X' In Digital Health

    HAMBURG, GERMANY, and OXFORD, UK / ACCESSWIRE / June 24, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that it has entered into a new strategic partnership with the British clinical AI technology company Sensyne Health plc (SENS) ("Sensyne"), the University of Oxford, Oxford University Innovation Ltd ("OUI", the university's research commercialisation company), and Oxford Sciences Innovation ("OSI", the world's largest IP investment company dedicated to a single university) to fund a new BRIDGE called LAB10x. This BRIDGE is aimed at accelerating the translation of research in the fields of clinical artificial intelligence and digital health at Oxford into forming new companies applying breakthrough digital solutions, clinical AI algorithms and accelerated data-driven drug discovery and development.

  • ACCESSWIRE

    Resolutions of the Annual General Meeting 2019 of Evotec SE

    HAMBURG, GERMANY / ACCESSWIRE / June 19, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that its shareholders approved all proposals the Company's Management put to vote at the Company's Annual General Meeting 2019 with very strong supporting majorities. The Management Board presented the Company's progress in the year 2018 and provided the shareholders with an update and outlook regarding future developments of the Company in their presentation "ExcellenceSQUARED". The strategy and its execution by the members of the Management Board and the Supervisory Board for the fiscal year 2018 were supported and approved.

  • ACCESSWIRE

    Evotec Receives $ 23.8 M Grant To Join The Global Fight Against Tuberculosis

    HAMBURG, GERMANY / ACCESSWIRE / June 10, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the company has entered into a five-year partnership with the Bill & Melinda Gates Foundation to discover new treatment regimens that better address tuberculosis ("TB"), a severe global health burden and one of the leading causes of death due to infectious diseases worldwide. The current standard treatment regimen for TB consists of a minimum of 6 months of treatment with 4 drugs administered under direct observation, but treatment is much longer when TB is drug resistant.

  • ACCESSWIRE

    Evotec And Celgene Further Expand Ipsc Collaboration Including New Cell Type

    HAMBURG, GERMANY / ACCESSWIRE / June 5, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its strategic alliance with Celgene Corporation ("Celgene") has been expanded to include a new cell type triggering a payment of $ 9.0 m to Evotec. Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases.

  • Should You Be Holding Evotec SE (ETR:EVT)?
    Simply Wall St.

    Should You Be Holding Evotec SE (ETR:EVT)?

    As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I...

  • ACCESSWIRE

    Evotec SE to Acquire Just Biotherapeutics, Inc.

    HAMBURG, GERMANY / ACCESSWIRE / May 20, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809, WKN 566480) announced today the signing of a definitive agreement under which Evotec ...

  • ACCESSWIRE

    Evotec Jump-Starts Biologics with Acquisition of Just Biotherapeutics

    EVOTEC'S OFFERING OF INTEGRATED SOLUTIONS EXTENDED TO BIOLOGICS ADDITION OF LONGSTANDING BIOLOGICS EXPERTISE BASED ON KEY TALENTS, INNOVATIVE ML (MACHINE LEARNING) DRIVEN TECHNOLOGIES AND SOPHISTICATED ...

  • ACCESSWIRE

    Evotec To Attend Upcoming Investor Conferences

    HAMBURG, GERMANY / ACCESSWIRE / May 15, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at and attending the following ...

  • Reuters

    European stocks regain ground, hoping for smoother U.S.-China trade

    European shares gained on Tuesday, recovering most of the previous session's losses, as optimistic comments from Washington and Beijing helped soothed investors' fears about the top two economies' intensifying trade spat. U.S. President Donald Trump said he had an "extraordinary" relationship with Chinese President Xi Jinping and trade talks had not yet collapsed. Earlier in the day, China said it agreed to continue talks on trade.

  • ACCESSWIRE

    Evotec SE Reports First Quarter 2019 Results And Provides Corporate Update

    - VERY GOOD START WITH 27% INCREASE IN GROUP REVENUES AND STRONG UNDERLYING INDICATIONS FOR FY 2019 - GOOD PROGRESS IN EXISTING CO-OWNED PORTFOLIO AND EXPANDING WITH NEW ALLIANCES - WEBCAST AND CONFERENCE ...

  • ACCESSWIRE

    Evotec SE to Report First Quarter 2019 Results on 14 May 2019

    HAMBURG, GERMANY / ACCESSWIRE / May 7, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) will report its financial results for the first quarter of 2019 on Tuesday, 14 May ...